All
- All
- Articles
- Calendar
- Compliance
- Newsletter
- Position Statements
- Press Release
- Regulatory
- Uncategorized
Early Impact of the Trump Administration
By Pete Evich, Vice President, Van Scoyoc Associates President Trump has been on the job for almost two months and the pace of his administration...
How Government Decisions Impact the Homeopathy Industry
Homeopathy, like all sectors of the healthcare industry, is subject to oversight and influence from various parts of the U.S. government. From Congress to regulatory...
Ensuring “Safety” Remains the Hallmark of Homeopathic OTCs
By Mark Land, M.S., RAC-US, AAHP President Monitoring and reporting on the safety of homeopathic drug products is a multifaceted undertaking that begins in the...
Potential Nitrosamine Impurities in Your Products?
By Robert Sven Jechlitschka, Director of Quality and Development, Schwabe Pharma México In September 2024, the Food and Drug Administration published a final guidance document...
Lowest Permissible Attenuation
By Eric L. Foxman, HPCUS Senior Scientist While many might be familiar with the nomenclature and concept of "First Safe Dilution" (FSD), the Homeopathic Pharmacopeia...
The FDA Adverse Event Reporting System (FAERS)
By Kristina Skowronek, Dir. of Quality and Regulatory Compliance, Boiron, Inc. The FDA Adverse Event Reporting System (FAERS) has a public dashboard online where healthcare...
Update — Lawsuit Challenges FDA’s Homeopathic Regulatory Policy
By Alvin J. Lorman, AAHP Counsel The lawsuit filed last October challenging FDA's characterization of homeopathic products as unapproved new drugs will not be decided...
